AveXis, Inc. (AVXS) Analysts See $-1.95 EPS; Buckingham Capital Management Increased By $1.68 Million Its Centutry Communities (CCS) Position

April 17, 2018 - By Dolores Ford

Century Communities, Inc. (NYSE:CCS) Logo

Buckingham Capital Management Inc increased Centutry Communities Inc (CCS) stake by 18.7% reported in 2017Q4 SEC filing. Buckingham Capital Management Inc acquired 54,105 shares as Centutry Communities Inc (CCS)’s stock declined 0.83%. The Buckingham Capital Management Inc holds 343,436 shares with $10.78 million value, up from 289,331 last quarter. Centutry Communities Inc now has $891.08 million valuation. The stock increased 1.00% or $0.3 during the last trading session, reaching $30.2. About 118,432 shares traded. Century Communities, Inc. (NYSE:CCS) has risen 20.81% since April 17, 2017 and is uptrending. It has outperformed by 9.26% the S&P500.

Analysts expect AveXis, Inc. (NASDAQ:AVXS) to report $-1.95 EPS on May, 10.They anticipate $0.88 EPS change or 82.24% from last quarter’s $-1.07 EPS. After having $-2.55 EPS previously, AveXis, Inc.’s analysts see -23.53% EPS growth. The stock increased 0.56% or $1.17 during the last trading session, reaching $211.93. About 1.21M shares traded or 47.94% up from the average. AveXis, Inc. (NASDAQ:AVXS) has risen 59.28% since April 17, 2017 and is uptrending. It has outperformed by 47.73% the S&P500.

Buckingham Capital Management Inc decreased Penske Automotive Group Inc Co (NYSE:PAG) stake by 12,449 shares to 114,664 valued at $5.49M in 2017Q4. It also reduced Children’s Place Inccom Stk (NASDAQ:PLCE) stake by 27,015 shares and now owns 127,737 shares. Madden Steven Ltd Com Stk (NASDAQ:SHOO) was reduced too.

Among 6 analysts covering Century Communities (NYSE:CCS), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Century Communities had 16 analyst reports since August 12, 2015 according to SRatingsIntel. The firm has “Overweight” rating by JP Morgan given on Thursday, February 15. The firm earned “Buy” rating on Monday, May 16 by Deutsche Bank. The stock of Century Communities, Inc. (NYSE:CCS) earned “Hold” rating by Zacks on Wednesday, August 12. The firm has “Outperform” rating by Wedbush given on Tuesday, September 20. The rating was upgraded by J.P. Morgan to “Buy” on Thursday, September 14. The firm earned “Outperform” rating on Thursday, February 23 by FBR Capital. Citigroup reinitiated it with “Buy” rating and $30 target in Tuesday, August 8 report. The stock of Century Communities, Inc. (NYSE:CCS) earned “Outperform” rating by Wedbush on Friday, December 29. The rating was upgraded by JP Morgan to “Overweight” on Thursday, September 14. The firm has “Buy” rating given on Thursday, September 1 by Citigroup.

Among 4 analysts covering AveXis (NASDAQ:AVXS), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. AveXis had 5 analyst reports since May 13, 2016 according to SRatingsIntel. Jefferies upgraded AveXis, Inc. (NASDAQ:AVXS) rating on Friday, August 12. Jefferies has “Buy” rating and $42 target. The rating was maintained by Goldman Sachs with “Buy” on Friday, May 13. The rating was initiated by Bank of America on Friday, October 21 with “Buy”. The company was initiated on Friday, July 15 by Wells Fargo. The firm has “Buy” rating by Jefferies given on Monday, September 19.

AveXis, Inc., a clinical-stage gene therapy company, engages in developing and commercializing treatments for patients suffering from rare and life-threatening neurological genetic diseases. The company has market cap of $7.80 billion. The Company’s initial product candidate is AVXS-101, a gene therapy product candidate that has completed Phase I clinical trial for the treatment of spinal muscular atrophy Type 1. It currently has negative earnings. The firm also intends to identify, acquire, develop, and commercialize gene therapy product candidates for the treatment of other rare and life-threatening neurological genetic diseases.

Century Communities, Inc. (NYSE:CCS) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>